Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Sarah Kennedy

Nurse Practitioner, Acute Care Norfolk, VA Nurse Practitioner

NPI 1134505068 CMS profile 10717001

600 Gresham Dr, Norfolk, VA 23507

Open in the dashboard

General payments

$57,350

252 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sarah Kennedy of Norfolk, VA is reported in the CMS Open Payments database as having received $57,350 across 252 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Acute Care profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $26,889 95
2024 General $23,304 94
2023 General $4,926 33
2022 General $240 7
2021 General $1,991 23

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sarah Kennedy
  • Nurse Practitioner, Acute Care median
  • Middle half of Nurse Practitioner, Acute Care
  • National median

In program year 2025, general payments to Sarah Kennedy were reported at $26,889. Among 11,827 Nurse Practitioner, Acute Care profiles paid that year, the median was $152 and the middle half received between $48 and $458.

Show as a table
Year Sarah Kennedy Nurse Practitioner, Acute Care median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $1,991 $123 $38–$327 $132
2022 $240 $130 $44–$369 $149
2023 $4,926 $144 $49–$410 $160
2024 $23,304 $146 $48–$433 $164
2025 $26,889 $152 $48–$458 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Medtronic, Inc. $40,811 181 payments
  2. Abbott Laboratories $13,503 32 payments
  3. Edwards Lifesciences Corporation $2,558 28 payments
  4. Boston Scientific Corporation $292 5 payments
  5. W. L. Gore & Associates, Inc. $95 1 payment
  6. Arcutis Biotherapeutics, Inc. $41 3 payments
  7. Janssen Scientific Affairs, LLC $30 1 payment
  8. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $21 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $27,285 27 payments
  2. Travel and Lodging $10,517 47 payments
  3. Consulting Fee $8,838 4 payments
  4. Food and Beverage $8,714 170 payments
  5. Compensation for serving as faculty or as a speaker for a medical education program $1,969 2 payments
  6. Education $28 2 payments
Products named General payments · program years 2021–2025
  1. COREVALVE EVOLUT R $40,437 171 payments
  2. NAVITOR Structural Heart $10,422 17 payments
  3. NAVITOR Vascular $1,559 4 payments
  4. Edwards SAPIEN 3 Ultra Transcatheter Heart Valve $1,483 17 payments
  5. AMPLATZER AMULET $875 1 payment
  6. SAPIEN 3 Ultra RESILIA $348 4 payments
  7. EVOQUE $206 2 payments
  8. AMPLATZER $190 5 payments
  9. CoreValve Evolut $165 5 payments
  10. MITRACLIP $152 1 payment
  11. Other $707 16 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

388

Median for Nurse Practitioner: 389

Drug cost

$68,646

Median for Nurse Practitioner: $21,885

Branded share of claims

34.3%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 79 $65,748
Clopidogrel Clopidogrel Bisulfate Brand 41 $774
Rosuvastatin Calcium Generic 18 $372
Metoprolol Succinate Generic 19 $337
Carvedilol Generic 47 $331
Spironolactone Generic 35 $273
Amlodipine Besylate Generic 21 $159
Losartan Potassium Generic 12 $148
Atorvastatin Calcium Generic 20 $140
Furosemide Generic 30 $105

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 8 billing codes

Paid by Medicare

$10,074

Medicare's payments for the services billed

Medicare patients

152

Average age 79

Services billed

168

87 women, 65 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Heart failure 75%
Ischemic heart disease 72%
Arthritis 58%
Atrial fibrillation 56%
Chronic kidney disease 43%
Diabetes 40%
COPD 32%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

252 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record